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1. INTRODUCTION 
 
1.1 Sepsis  
Sepsis is Greek for putrefaction or decay. In clinical medicine it is a term used to describe the 
systemic response to an infection, defined as “a systemic inflammatory response syndrome 
(SIRS) caused by infection” (1). By the American College of Chest Physicians/Society of 
Critical Care Medicine Consensus Conference in August 1991, SIRS was originally defined 
by the presence of more than one of the following criteria: (I) a body temperature greater than 
38°C or less than 36°C; (II) a heart rate above 90 beats/min; (III) a respiratory rate greater 
than 20 breaths/min or hyperventilation defined by PaCO2 less than 4.3 kPa; and (IV) an 
alteration in the white blood cell count (WBC) defined by WBC greater than 12 x 109 /L or 
WBC less than 4 x 109 /L or more than 10% immature neutrophils in the WBC (1). Later 
reviews of the SIRS definition have made slight alterations to the original criteria and taken in 
several more criteria including inflammatory, haemodynamic, organ dysfunction and tissue 
perfusion variables (2,3). As a number of non-infectious diseases, such as trauma, burns and 
pancreatitis may also cause SIRS, a documented or suspected infection is a diagnostic 
requirement for sepsis (3). 
 
Based on severity, sepsis is stratified into four subgroups: (I) sepsis; (II) severe sepsis; (III) 
septic shock; and (IV) sepsis with multiple organ dysfunction syndrome (MODS) (1). In the 
US sepsis and severe sepsis are the most common causes of death among critically ill patients 
in non-coronary intensive care units (ICU), and overall one of the leading causes of death (4). 
These conditions are public health problems of great cost (5). As growing patient groups such 
as elderly patients and patients with pre-existing chronic diseases are at increased risk, the 
public health care issues and death tolls may most possibly increase in the future (4). It would 
therefore be of great significance to find more effective means to combat the disease.  
 
The leading causes of sepsis in the US and Europe are almost equally divided between Gram-
positive and Gram-negative infections, although with an increase in Gram-positive infections 
over the last few decades (6-8). The vast majority of the Gram-positive infections are caused 
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by a variety of Staphylococci species, and in a large European multicentre ICU study from 
2006 (the SOAP study), species of Staphylococci and Streptococci accounted for more than 
90 % of all Gram-positive infections in septic ICU patients (6). With regards to the Gram-
negative infections in the same study, Escherichia coli and Pseudomonas species were found 
to be causative in over 50 % of cases (6). Just as interesting, the same study reports that as 
much as 40 % of all septic ICU patients only had clinical signs of infection, and no causative 
microbe was found. Furthermore, as much as 18 % of the septic patients had polymicrobial 
infections (6). The findings of the SOAP study are analogous to previous and later studies 
(7,8).  
 
1.2 Innate immunity and inflammation 
The body is under constant threat from microbes in its natural environment. Under 
physiological circumstances, the microbes are held outside the body by the skin and mucosal 
surfaces as a first line barrier against infections (9). As soon as the microbes trespass the 
barrier, the immune system is set in action (9). In the course of evolution, the immune system 
has developed several mechanisms in order to cope with invading microbes. These 
mechanisms are commonly divided into two main branches: innate and adaptive immunity. 
Adaptive immunity serves as the “long term” memory of the immune system. Its main 
function is to remember specific microbes with strong affinity in order to detect and destroy 
them whenever encountered (9).  
 
Innate immunity on the other hand, is functional even without previous sensitization and 
depends on germ-line encoded receptors, referred to as pattern recognition receptors (PRRs) 
(10). The cardinal trigger of the immune response is the recognition of conserved molecular 
patterns of exogenous as well as endogenous molecules by these PRRs (11,12). The 
exogenous conserved patterns from different microbes are referred to as pathogen-associated 
molecular patterns (PAMPs), whereas the endogenous conserved patterns, which do not 
originate from microbes but rather from damaged host cells, are referred to as damage-
associated molecular patterns (DAMPs) (13-15). Thus, innate immunity is not only structured 
to combat invading pathogens, it is also designed to detect, repair or clear damaged cells, 
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representing danger from within the host itself. The main goal of innate immunity, whether it 
detects microbes or damaged self, is to re-establish homeostasis (10).  
 
Confusingly, in the ”danger model” proposed by Polly Matzinger, the abbreviation DAMPs is 
used as short for danger-associated molecular patterns, a common denomination for PAMPs 
and alarmins (15). This model reflects the view that innate immunity is designed to detect 
danger, exogenous (PAMPs) and endogenous (alarmins), rather than discriminate self from 
non-self, which in the 1990ies was the competing view on innate immunity as stated by 
Charles Janeway in his “self-non-self” model (16). In this thesis DAMPs will be used as short 
for damage-associated molecular patterns and not as a common denomination for PAMPs and 
alarmins.  
 
Upon recognition of PAMPs and DAMPs via PRRs, innate immunity responds by inducing 
inflammation (10). The inflammatory mediators are secreted by a number of cells, including 
macrophages, monocytes, granulocytes and dendritic cells of the immune system (12,17). 
These mediators are commonly denominated cytokines and include a broad variety of locally 
and systemically active molecules, which induce chemotaxis, regulate expression of cell 
surface receptors and adhesion molecules, increase capillary leakage, trigger coagulation and 
fibrinolysis, and activate macrophages and fibroblasts, to mention some of its multifaceted 
activities (18). In addition a wide variety of other mediators such as prostaglandins and 
leukotrienes directly or indirectly induce a diverse inflammatory response (19). 
 
This thesis is mainly focused on PAMPs. Importantly however, DAMPs and PAMPs appear 
largely to depend on the same PRRs to evoke inflammatory responses (9). Therefore, the 
translational value of research on pathogen-induced inflammation to sterile-induced 
inflammation may prove to be of great significance. 
 
PRRs of innate immunity involved in detection of PAMPs include several groups of receptors: 
Intracellular receptors, cell surface bound receptors and soluble receptors (17). Examples of 
intracellular PRRs are Nucleotide Oligomerization Domain-like (NOD-like) receptors and 
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Retinoic acid Inducible Gene-like (RIG-like) receptors which recognize intracellular 
microbial PAMPs and intracellular viral RNA respectively (20-23). To the family of 
exclusively intracellular PRRs belong also the relatively newly discovered AIM-like (Absent 
In Melanoma-like) receptors (23). These intracellular PRRs and their effector functions will 
not be discussed in this thesis.  
 
Toll-like receptors (TLRs) including its soluble co-receptors and the complement system are 
important examples of membrane bound and soluble PRRs (17). They play key roles in the 
network of innate immunity functioning as central upstream sensor- and effector-systems, 
thus to a large part being responsible for the complex and widespread inflammatory response 
(15,24). These systems, their role and the interplay between them in Gram-negative and 
Gram-positive induced inflammation, and partly also in sterile induced inflammation will be 
described in the following. 
 
1.3 The complement system 
The complement system is an important part of innate immunity, where it plays a vital role 
defending the host against pathogens and maintaining homeostasis (25). Over the last decades 
it has become clear that it serves as a bridge to adaptive immunity involving T and B cells 
(26), and also is involved in the pathogenesis of an increasing number of conditions where 
microbes are not involved (27). It is constituted by over 30 different plasma and cell surface 
proteins forming a cascade system with a plethora of physiological effects (28,29). Activation 
of the cascade is triggered via one of three possible pathways; the classical, the lectin and the 
alternative pathways. All pathways converge on the central complement factor C3 which is 
cleaved to C3a and C3b, thereby launching the terminal pathway as C5 is cleaved to C5a and 
C5b and the assembly to form the terminal complement complex is initiated (TCC) (25,30). 
 
The classical pathway (CP) is initiated when immune complexes are formed from C1q 
binding to antibodies in complex with pathogenic surface antigens or other non-self antigens 
(30). In addition, pentraxins, such as the acute phase protein CRP, may clear pathogens by 
directly binding to C1q (31). The complex recruits C1r and C1s, the latter cleaving C4 and C2 
to form C4bC2b – the C3 convertase of the CP. 
14 
 
 
Figure 1. The complement system (with permission from the copyright holder T. E. Mollnes). 
 
The lectin pathway (LP) is activated when mannose binding lectin (MBL), ficolins or 
collectins are bound to carbohydrate structures on the surface of pathogens (25). In the 
circulation, MBL, ficolins and collectins are bound to MBL-associated proteins (MASPs) (32), 
which undergo conformational changes upon binding to pathogens, thereby inducing cleavage 
of C4 and subsequent recruitment and cleavage of C2 to ultimately form C4bC2b – the C3 
convertase of the LP. 
   
The alternative pathway (AP) has a “spontaneous tick over”, as hydrolysis of C3 to form 
C3(H2O) goes on continuously (33). In addition, the pathway may be triggered by several 
molecular structures, including carbohydrates, proteins and lipids on pathogens and other non-
self surfaces which split C3 into C3b and the anaphylatoxin C3a. Further activation takes 
place as C3(H2O) or C3b are bound to factor B, which is further cleaved by factor D to form 
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C3(H2O)Bb or C3bBb respectively – both C3 convertases of the AP. These convertases are 
further stabilized when they form complex with Properdin (or factor P) (33).  Properdin has 
previously also been regarded as a PRR of the AP by recruitment of C3b to induce assembly 
of the AP C3 convertase (25,33), but results from later studies seriously question the role of 
Properdin as a PRR (34). In addition to being an activation pathway, the AP also functions as 
an essential amplification loop for the CP and the LP, maybe responsible for as much as 80% 
of the final formation of C5a and TCC (34,35). 
 
Following the cleavage by the C3 convertases, C3b forms complexes with the same C3 
convertases C4bC2b and C3bBbP, producing the C5 convertases C4bC2bC3b and 
C3bBbPC3b. These convertases cleave C5 to C5a and C5b, initiating the mentioned assembly 
of the TCC as C6 and C7 bind to C5b followed by C8 and lastly multiple C9 molecules (25).  
 
When multiple TCCs are inserted into the membrane of certain microbes and cells, each of 
the TCCs form a pore, and ultimately lysis may occur. In this setting TCC is often referred to 
as the membrane attack complex (MAC). This mechanism is especially important in the 
defence against infections with Neisseria (N.) meningitides, one of the microbes responsible 
for causing meningitis (36). As importantly, when TCCs are formed in sublytic concentrations 
on membranes, they may induce proinflammatory responses, for instance on endothelial cells 
and other nuclear cells (37).  
 
Another and important way the complement system defends the host from invading pathogens 
is by opsonisation of the microbes by deposition of C3b and C4b fragments to induce 
phagocytosis (38). In addition to bactericidal activity, it is also responsible for tissue 
regeneration and clearance of apoptotic cells and debris (39,40), but more importantly, 
especially in the setting of sepsis, it is one of the main inflammatory triggers.    
 
The small split fragments of the complement cascade C3a and C5a are highly biologically 
active anaphylatoxins and the main inflammation inducing complement products (41-43). C3a 
and C5a have several biological functions in common such as promotion of vasodilation and 
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increasing capillary leakage (44), and both are associated with pathogenesis in asthma and 
acute respiratory distress syndrome (ARDS) (45). C3a also induces mast cell degranulation 
and transcription factor activation thereby increasing inflammation (46). Of the two, C5a is a 
particularly potent inflammation inducer and a plethora of effects includes upregulation of 
adhesion molecules, stimulation of phagocytosis and oxidative burst in neutrophils and 
monocytes, induction of granular enzyme release and attraction of neutrophils to the site of 
danger (42,44,47). On the other hand,  recent studies show that C3a also has several anti-
inflammatory effects partly opposing the proinflammatory effects of C5a, a noteworthy point 
in the debate about where in the complement cascade to intervene therapeutically (48). 
 
All of the above mentioned effects are favourable under physiological circumstances, helping 
the host to combat infections as part of first line host immune defence mechanisms. However, 
when activated systemically, particularly C5a is heavily involved in the pathological 
processes causing the clinical syndrome sepsis (42,49).   
 
1.4 Toll-like receptors 
The TLR family is constituted by a complex group of PRRs which recognize a wide variety of 
evolutionary conserved molecular structures (50). The main function of the TLRs is signalling 
to the cells as microbial PAMPs are recognized as exogenous danger (10). Over the last years 
it has however become clear that TLRs in addition sense endogenous ligands, which are 
cellular components of self-origin such as proteins and peptides, polysaccharides and 
proteoglycans, nucleic acids and phospholipids. Accumulating evidence demonstrates 
that endogenous ligand-mediated TLR signalling plays a role in several disease processes 
including tissue injury, repair and regeneration, autoimmune diseases and tumorigenesis – all 
conditions involving sterile inflammation (51). 
 
To date, ten different TLRs have been identified in human (52). Concerning the exogenous 
ligands, each TLR has specificity for distinct PAMPs from bacteria, mycobacteria, fungi, 
parasites and viruses: Lipoproteins are recognized by TLR1, 2 and 9; double-stranded RNA 
by TLR3; LPS by TLR4, flagellin by TLR 5, single-stranded RNA by TLR7 and 8; and DNA 
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by TLR9 (52). Upon recognition of these PAMPs, TLRs recruit a specific set of adaptor 
molecules, such as MyD88 and TRIF, to induce downstream signalling (53).  
 
In Gram-negative inflammation, LPS is the main inflammation inducing molecule, and TLR4 
is considered to be the only LPS-receptor (54). TLR4 has therefore been regarded a possible 
interventional target for modulating the inflammatory response in Gram-negative induced 
inflammation. In order to induce downstream intracellular signalling by recognition of LPS, 
TLR4 is however dependent on cofactors. One of the cofactors, myeloid differentiation factor 
2 (MD-2), is a soluble protein present on the extracellular domain of TLR4 and confers 
responsiveness to LPS (55). CD14, another TLR4 cofactor, was actually discovered before 
TLR4 itself; it was found to bind the circulating LPS in complex with LPS-binding protein 
(56,57). Upon binding with LPS, the CD14/LPS complex binds to the MD2/TLR4-complex 
and induces activation of intracellular signalling via the adaptor molecules MyD88 and TRIF 
to finally activate the nuclear transcription factor, which is responsible for transcription of a 
wide variety of inflammation associated genes and subsequent synthesis and release of several 
pro-inflammatory cytokines (53,58,59). Some Gram-negative bacteria such as N. meningitides 
induce signalling via both adaptor molecules, whereas E. coli predominantly induce signalling 
via MyD88 and Salmonella predominantly via TRIF (60).   
 
As mentioned, TLR2 is the Gram-positive PRR analogue to TLR4 for Gram-negative bacteria 
(61,62). However, debate is still ongoing about the Gram-positive TLR2 ligand. Lipoteichoic 
acid (LTA) has been claimed to be the Gram-positive LPS analogue (59,60), but later studies 
have shown  that especially LTA of S. aureus and S. pneumoniae are not ligands for TLR2, 
but in fact for the lectin pathway (63). On the other hand, the staphylococcal lipoproteins, 
Panton-Valentine toxin and Phenol Soluble Modulins have been identified as potent TLR2 
ligands, and little controversy exists over the statement that also TLR2 mediates Gram-
positive inflammation (64). The TLR2 signalling is partly analogous to TLR4 signalling as 
TLR2 also uses a MyD88-dependent signalling pathway to translocate NF-ĸB into the nucleus 
with subsequent activation of the expression of pro-inflammatory cytokine genes (64). Even 
more interestingly, it has been shown that TLR2 signalling by these staphylococcal ligands is 
CD14 dependent (65). The true promiscuous role of CD14 as co-receptor for the majority of 
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the TLRs, makes it an important molecule in the TRL family and an utterly interesting target 
molecule for anti-inflammatory purposes (50).  
 
TLR2 and TLR4 are transmembrane lipoproteins located on the extracellular surface of the 
immune cells, but several other TLRs, including TLR3, 7, 8 and 9, are located on the inside of 
the cell in order to detect PAMPs and DAMPs intracellularly. In the setting of an infection, 
they are designed to and evoke an inflammatory response upon recognition of intracellular 
microorganisms including viruses and certain bacteria and parasites (17,66,67).  
 
TLR stimulation is finally responsible for the production of a wide variety of pro-
inflammatory cytokines, including IL-6 and TNF, which drive the inflammatory response 
(66,68).   
 
1.5 Cross-talk: Complement, TLRs and coagulation 
There is increasing evidence for a close and widespread cross-talk between complement and 
TLRs, but also between innate immunity and coagulation (69-71). Phagocytosis of 
mycobacteria and Borrelia burgdorferi has been shown to be enhanced by cross-talk between 
complement receptor 3 (CR3) and CD14, and killing of Salmonella has been documented to 
be dependent on TLR4 and CR3 (72-74). Several PAMPs, including the TLR4-ligand LPS 
and TLR2/6-ligand zymosan have been demonstrated to markedly increase the level of the 
pro-inflammatory cytokines IL-6, TNF and IL-1β in a complement dependent manner (75). In 
the setting of septic inflammation, especially the proposed ability of C5a and TLRs to 
reciprocally promote pro-inflammatory cytokine production is of great relevance (75,76).  
 
Innate immunity and coagulation are intimately connected and may be viewed as partners in 
the inflammatory response with the main goal of stabilizing an organism which has 
encountered a threat to its homeostasis (71). In settings where the complement system is 
activated, such as during an infection, the coagulation system is also tilted towards a pro-
coagulant state (77). Similarly, whenever the coagulation system is triggered, for example 
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during trauma, an associated activation of inflammation will occur as the host is at risk of 
infection (78). This simultaneous activation of haemostasis and inflammation is in many 
clinical circumstances beneficial. For example, in the instance of an infection, the local 
formation of thrombi in the microvasculature draining the site of the infection supplies an 
important barrier which prevents the bacteria from entering the circulation.  
 
In fact, not only are these systems concurrently activated. At various levels of inflammation 
and haemostasis, members of both systems interact directly or via secondary mediators.  
There are several examples of such interactions: C5a may directly trigger tissue factor (TF), 
the spark plug of the coagulation cascade; anticoagulation mechanisms are inhibited by 
binding of C4b-binding protein to Protein S, an important co-factor for degradation of 
coagulation factors Va and VIIIa via activated protein C (79); C3a and C5a promote the 
production of TNF and IL-6, which in turn enhance TF expression on monocytes and increase 
platelet thrombogenicity; lastly, observations in vitro also suggest that complement 
components may be cleaved directly by thrombin, plasmin and factor XIIa (71). Therefore, 
when studying inflammation, concurrently recording markers of haemostasis, systemically as 
well as in organs, provide important additional information.  
 
1.6 Sepsis: Complement and TLRs 
Under physiological conditions complement and TLRs act partly systemically by signalling 
danger, but predominantly promote local effects and as part of host defence mechanisms work 
to stop microorganisms from entering the circulation and strive after homeostasis. However, 
under pathological conditions, such as in sepsis, the tight regulation of these systems fail and 
systemic activation occurs promoting SIRS throughout the body, also in organs far from the 
site of danger (80-83). The favourable and essential local actions of innate immunity become 
the main threat to the host. For example, increased vascular permeability, capillary leakage 
and vasodilation are advantageous innate immunity effects in order to allow sequestration of 
neutrophils to the site of infection, but when these effects are promoted systemically, the net 
result is loss of intravascular volume, hypotension and reduced blood flow to vital organs in 
addition to organ inflammation upon sequestration of neutrophils to organs far from the site of 
danger (84,85). 
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The mentioned advantageous interplay between coagulation and innate immunity also 
becomes harmful in systemic infection-induced inflammation as haemostasis is tilted toward a 
more procoagulant state, promoting disseminated intravascular coagulation (DIC) (86).  
Hallmarks of DIC are the microvascular depositions of fibrin, platelet consumption and 
formation of microthrombi, also far from the site of infection, contributing to organ 
dysfunction and failure (86,87). The onset of DIC in sepsis has the clinically devastating 
importance of increasing mortality two-fold (88).  
 
The overall myriad of inflammatory responses in sepsis is impossible to fully account for. In 
addition to complement, TLRs and coagulation, also the fibrinolytic system and the 
kallikrein/kinin system are activated (89,90). The endothelial cells are also important players 
in promoting dysfunctional microcirculation as adhesion molecules are upregulated and 
platelets and leukocytes adhere to the microvascular lining (91,92). 
 
1.7 Sepsis treatment 
To date treatment of severe sepsis and septic shock basically still relies on three arms: Initial 
resuscitation, anti-microbial therapy and supportive therapy.  
 
The main goal of the first arm, initial resuscitation, is to re-establish adequate perfusion to all 
vital organs. Briefly summarised, haemodynamic support according to Guidelines from 2012 
includes (2): initial fluid resuscitation with crystalloids and eventually albumin if needed; 
fluid challenge to hypovolemic patients; vasopressor support with noradrenalin and eventually 
adrenalin to maintain blood pressure above 65 mmHg. 
 
The main goal of the second arm of treatment, anti-microbial therapy, is obvious and 
according to the above mentioned Guidelines from 2012 includes: taking blood cultures or 
cultures from the relevant site of infection before administering antibiotics in order to obtain a 
specific microbial diagnosis; broad-spectrum antibiotics until the microbe is known; extensive 
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investigations including imaging studies to obtain a certain source of infection; and lastly 
reassessment of microbial therapy daily and de-escalation of the microbial therapy according 
to microbiological results. Gaining control over the site of infection by surgically revising 
infected wounds, abscesses and so on is also of great importance. 
 
The third arm, supportive therapy, is primarily aimed at helping the organs to maintain normal 
function and homeostasis, or secondarily replace malfunctioning organs. This includes 
mechanic ventilation, dialysis, sedation and administration of blood products and glucose. 
Use of corticoid treatment and prophylaxis against deep vein thrombosis and gastric ulcers are 
also recommended to specific patients groups when appropriate (2). 
 
Given the elaboration above on innate immunity, inflammation and inflammatory mediators, a 
fourth arm of treatment in sepsis is missing and has long been sought: Mediator directed 
therapy. Several clinical trials blocking a range of mediators in sepsis including bradykinin, 
prostaglandins and platelet activating factor, and furthermore anti-thrombotic treatment using 
tissue factor pathway inhibitor and anti-thrombin have all failed to show beneficial effects 
(93-97).  
 
IL-1β and TNF are clearly linked to septic inflammation and both have been considered 
possible therapeutic targets in patients with severe sepsis (98-100). As the level of IL-6 in 
septic patients correlates with severity and mortality, IL-6 was also thought to be a possible 
therapeutic target (101,102). However, several large clinical trials show that increased 
survival has not been achieved by targeting these downstream cytokines selectively (103-106). 
There were also considerable expectations connected to treatment with recombinant human 
activated protein C (rhAPC), but promising results were not reproducible, and the ability to 
increase survival in a final multicentre study failed (107). Lastly, also the specific TLR4 
inhibitor eritoran failed in clinical trials (108). In common, all these trials have tried to combat 
the inappropriate inflammation in sepsis by singling out one key downstream mediator. Given 
the inexplicably large number of downstream mediators flowing over as part of the 
inflammatory response, not to mention the cross-talk and redundancy of innate immunity, it is 
not surprising that these trials have failed.  
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Accordingly, the possibility of dampening the overall inflammatory load in sepsis seems more 
likely when targeting upstream. In this context targeting upstream means blocking down or at 
least slowing down the cascade mechanisms as close to the interaction between the PRRs and 
the PAMPs as possible. However, targeting each specific PAMP or its receptor would demand 
specific knowledge about the infecting microbe at the commencement of treatment, which in 
practice is impossible. Therefore, targeting unspecific pattern recognition receptors of several 
PAMPs may prove to be a possible way forward in the search for mediator directed therapy.  
 
CD14 is one such molecule of the TLR family important for unspecific pattern recognition of 
several PAMPs, and the complement factor C3 and to a large degree also C5 another set of 
such upstream molecules acting as bottlenecks for downstream effects of the complement 
system. Indeed, inhibiting CD14 has been shown to have vast anti-inflammatory effects in 
septic pigs, and inhibition of complement factor C3 has also shown promising anti-
inflammatory effects in septic baboons (109,110).  
 
In 2008, following observations of improved anti-inflammatory effects when combining 
inhibition of TLRs and a key complement molecule, professor Mollnes and colleagues put 
forward the hypothesis that this combined inhibition may be a future strategy to attenuate the 
inappropriate inflammatory response seen in sepsis as well as in conditions with sterile 
induced inflammation (47,81). Several studies of the effect of the combined inhibition on 
sterile and non-sterile induced inflammation have been conducted since (111-115).  
 
 
 
 
 
 
23 
Figure 2. The concept of combined inhibition of complement and CD14 (with permission 
from the copyright holder T.E. Mollnes). 
24 
 
2. AIM  
 
In this thesis, dissecting the effects of combined inhibition of a key complement molecule and 
CD14 under changing conditions of bacterial induced inflammation and sepsis has been the 
main task.  
x A possible preservation of the anti-inflammatory effects of the combined inhibition of 
complement and CD14 was investigated under increasing concentrations of Gram-
negative and Gram-positive bacteria ex vivo (Study I).  
x The anti-inflammatory effects of the combined inhibition of C3 and CD14 when 
introducing a time delay between the onset of Gram-negative induced inflammation 
and the addition of the inhibitors were examined in the same ex vivo model (Study II). 
x The effects on inflammation, haemostasis and haemodynamics of combined inhibition 
of C5 and CD14 were examined in a porcine in vivo model of E. coli-induced sepsis 
(Study III).  
x Lastly, the efficacy of the combined inhibition of C5 and CD14 on local organ 
responses to septic inflammation was studied in the same in vivo model (Study IV).  
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3. MATERIALS AND METHODS 
 
3.1 Bacteria 
E. coli strain LE392 (ATCC 33572) and S. aureus Cowan Strain 1 (ATCC 12598) were 
obtained from American Type Culture Collection (Manassas, VA). Heat-inactivated E. coli 
was used in paper I and II, whereas live E. coli were used in paper III and IV. S. aureus (heat-
inactivated) was used only in paper I. 
 
3.2 Inhibitors 
In paper I, azide-free mouse anti-human CD14 (clone 18D11; F(ab`)2 3118, lot1383) was 
used in the E. coli experiments. The recombinant anti-human CD14 IgG2/4 Ab (r18D11) was 
used in the S. aureus experiments (116). For complement inhibition, either the complement 
C5 inhibitor, eculizumab (Soliris®) or the compstatin analogue Cp40, a complement C3 
inhibitor, were used (117). 
 
In paper II, azide-free mouse anti-human CD14 (clone 18D11; F(ab`)2 3118, lot1383) and the 
Compstatin analogue AMY-90, a complement C3 inhibitor, were used. 
 
In paper III and IV, recombinant bacterial Ornithodoros moubata Complement Inhibitor 
(OmCI), a 16.8 kDa protein also known as coversin (118), and mouse anti-porcine CD14 
mAb (clone MIL-2, isotype IgG2b) were used. 
 
3.3 Analyses 
ELISA 
In paper I and II, the terminal complement complex (TCC) was measured using a sandwich 
ELISA (119,120). Briefly, the monoclonal antibody (mAb) aE11 recognizes a neoepitope 
exposed in C9 after incorporation in the C5b-9 complex. aE11 was used as capture antibody 
binding to the soluble TCC. A biotinylated anti-C6 mAb (clone 9C4) was used as detection 
antibody. In paper I, the standard was normal human serum activated with zymosan and 
defined to contain 1000 arbitrary units (AU)/mL, whereas in paper II the standard was 
International Complement Standard #2 (ICS#2) (121), which is a standardized version of 
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zymosan activated normal human serum. Zymosan activated human serum was used as a 
positive control.  
 
The granulocyte activation markers myeloperoxidase (MPO) and lactoferrin (LF) were 
quantified using commercially available kits from Hycult Biotech in paper I, whereas in paper 
II only MPO was measured.  
 
In paper III Leukotriene B4 (LTB4) from serum was measured using a competitive enzyme 
immunoassay from R&D Systems. Citrate plasma was used for measuring thrombin-
antithrombin (TAT) in an immunoassay kit from Dade Behring (122). Plasminogen activator 
inhibitor-1 (PAI-1) was measured in citrate plasma by a porcine PAI-1 kit from Molecular 
Innovations. The cytokines TNF, IL-1ß, IL-6 and IL-8 were analyzed by Quantikine Porcine 
Immunoassay kits from R&D Systems, whereas IL-10 was analyzed by a porcine kit from 
BioSource Invitrogen. A Complement System Screen (Wielslab®) from Eurodiagnostica AB 
was used to test functional activity of the classical, lectin and alternative complement 
pathways. 
 
In paper IV IL-1ß was measured using the same kit as in paper III. 
 
Multiplex analysis 
In paper I and II, cytokines TNF, IL-1β, IL-6, IL-8, MIP-1α and MIP-1β were measured 
using a multiplex cytokine assay from Bio-Rad Laboratories. In paper III and IV, TCC was 
measured using multiplex xMAP technology (123), and in paper IV the same technology was 
also used for measuring IL-6, IL-8 and monocyte chemotactic protein-1 (MCP-1). In short, 
antibodies for the biomarkers were coupled to carboxylated nonmagnetic beads using a Bio-
Plex amine coupling kit from Bio-Rad. The nonmagnetic beads with the coupled antibodies 
were then incubated with organ homogenates or plasma samples and subsequently incubated 
with a secondary antibody followed by streptavidin-R-PE from Qiagen. Measurement and 
data analysis of all multiplex analyses were performed using Bio-Plex 100 System and Bio-
Plex Manager software version 6.1. 
 
Flow cytometry 
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Flow cytometry was used for measuring CD11b on monocytes and granulocytes in paper I. 
The cells were stained with anti-CD11b PE and anti-CD14 FITC. Flow cytometry was also 
used in paper III; the procine ortholog to human CD11b, wCD11R3, was measured only on 
neutrophils in vivo, the cells stained with mouse anti-porcine wCD11R3 FITC. In the same 
study, TF on granulocytes was measured in separate ex vivo experiments, the cells stained 
with sheep anti-human TF and donkey anti-sheep IgG-FITC conjugate. In study III, 
haematological parameters including leukocyte differential count was measured on a routine 
hospital haematological instrument, which in principle is a flow cytometer. This instrument 
discriminated neutrophils in porcine blood, but monocytes and lymphocytes were not 
discriminated. 
 
Histopathological evaluation  
In paper III, two micrometre thick sections from formalin-fixed lung- and liver specimens 
were deparaffinised and stained by haematoxylin/eosin (H&E) and saffron. The lung biopsies 
were evaluated by morphometry in order to estimate the volume density of interstitial and 
alveolar inflammatory changes. In the liver biopsies granulocyte infiltration and oedema in 
the portal tracts were evaluated. 
 
Quantitative real-time PCR analyses 
In paper IV, homogenised tissue samples from harvested organs were analysed for gene 
regulation of C5a Receptor (CD88), TF, PAI-1 and IP-10 using TaqMan qPCR-primers.  
 
3.4 Models 
Ex vivo whole blood model 
In study I and II a well-established whole blood model was used. The model was developed 
in order to maintain all functional effector systems open and able to interact, but without the 
blood clotting. The specific thrombin inhibitor lepirudin (Refludan®) leaves all functional 
effector systems but thrombin open to interact, and no interference with complement 
activation has been discovered (124). Although not equivalent to studying living organisms 
undergoing massive inflammation, the whole blood model allows studies of all inflammatory 
mediators and cross-talk between these systems.  
 
Whole blood was drawn from healthy volunteering donors, directly anti-coagulated with 
lepirudin and further immediately processed. In paper I, all blood was preincubated for five 
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minutes with inhibitors or PBS before receiving increasing concentrations of either E. coli or 
S. aureus and then incubated for one hour (for measuring granulocyte activation markers) and 
four hours (for measuring cytokines and TCC) at 37 °C. For measuring CD11b, the blood was 
incubated for 15 minutes before the cells were fixed using formaldehyde and stained as 
described above. In paper II the inhibitors and PBS were added 5 minutes before or 5, 15 or 
30 minutes after adding E. coli. The blood was incubated for one and two hours. The 
experiments were stopped using EDTA, and plasma was stored at -70 °C until analysed.   
 
In vivo model 
The E. coli-induced sepsis model which was used in study III and IV is previously well 
described with rapid increase of inflammatory and haemostatic biomarkers (125). The 
intravenous infusion of E. coli was conducted with a stepwise increase in bacterial 
concentration over four hours, whereby infusing a total of 1.075 x 108 E. coli/kg, which 
corresponds to 1.1 x 106 bacteria/mL blood. The pigs were extensively monitored using 
continuous ECG recording, artery line, central venous catheter and pulmonary artery catheter. 
The monitoring included recording of HR, MAP, MPAP, CVP, SaO2 and urinary output. The 
insertion of a PiCCO-catheter was implemented in all experiments and allowed for 
measurement of stroke volume variation (SVV). Blood gases were measured regularly, and a 
pH of 7.40 was used as guide to adjust the respirator settings. Blood was also drawn regularly; 
at the beginning of the experiments, at the time the bacterial infusions were commenced and 
every hour thereafter. The blood drawn was used for analyses as mentioned above. At the end 
of the experiments, the animals were euthanized and organ samples were harvested 
immediately and transported on dry ice to be stored at -70 °C before further processing and 
analyses. 
  
3.5 Statistical considerations 
Parametric statistics were used in all studies. Whenever two groups were compared a t-test 
was applied. In study II parallel data were obtained from the same individuals and a paired t-
test was used to compare each intervention group with the positive control. In study IV, the 
collected data were not paired; an independent sample t-test was used to compare the 
combined inhibition group with the positive control group.  
 
Whenever multiple groups were compared, ANOVA was used and post-test analyses were 
applied. In study I one-way ANOVA followed by Dunnet’s post-test was chosen to compare 
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single and combined inhibition with the positive control group. In study II, the same 
statistical analysis was used for comparison of single inhibition of complement and CD14 
with combined inhibition. The positive control group was omitted from this testing as the 
intention of the analysis was to test whether the combined inhibition gave a significantly 
different result from the single inhibitors. In study III a two-way ANOVA followed by 
Bonferroni’s correction for multiple comparisons was performed for analysing both 
intervention groups.  
 
In study II, one might argue that it would be appropriate to correct for multiple comparison, 
as the combined inhibition was added and tested at multiple times after adding the bacteria. 
However, correcting for multiple comparisons under such circumstances would imply 
decreased power of the analyses for each time-point included in the analysis. Using correction 
for multiple comparison would therefore increase the likelihood of making type II errors and 
falsely maintain our null-hypothesis simply because to many time points of adding the 
combined inhibition were included in the analysis. Before doing any statistical testing, simple 
knowledge of the biological cascade systems under investigation tells us that the effect would 
be lost sooner or later. It was therefore considered appropriate to run t-tests to investigate at 
what time point the anti-inflammatory effect was lost.  
 
A P-value < 0.05 was considered significant in all analyses.  
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4. SUMMARY OF THE MAIN RESULTS.  
 
Study I 
Heat-inactivated E. coli and S. aureus were added in increasing concentrations. In the E. coli 
experiments with combined complement and CD14 inhibition, IL-6 was significantly reduced 
at all bacterial concentrations, whereas the significant effect on IL-1β, IL-8 and MIP-1α was 
lost only at the highest bacterial concentration. For TNF and MIP-1β, significant reductions 
were observed at the lowest bacterial concentration. Monocyte and granulocyte CD11b 
expression were significantly reduced at all bacterial concentrations. Lactoferrin was 
significantly reduced at the lowest bacterial concentration.   
 
In the S. aureus experiments with combined complement and CD14 inhibition, IL-6 and TNF 
were significantly reduced at the lowest bacterial concentration and IL-8 was significantly 
reduced even with twice the bacterial load. Monocyte and granulocyte CD11b expression was 
almost completely abolished at all but the highest concentration of S. aureus; at the highest 
concentration it was still significantly reduced.  
 
In conclusion, study I demonstrates well preserved anti-inflammatory effects of the combined 
inhibition, although with somewhat lesser effects on Gram-positive inflammation.  
 
Study II 
Anti-CD14, compstatin (C3 inhibitor) and the combination thereof were added 5 minutes 
prior to, or 5, 15 or 30 minutes after adding E. coli. Combined inhibition significantly 
attenuated IL-1β, IL-8 and TNF when adding the inhibitors up to 30 minutes delayed. IL-6 
was significantly attenuated when adding the inhibitors up to 15 minutes delayed, whereas 
MIP-1α and MPO were significantly attenuated when adding the inhibitors 5 minutes delayed. 
Finally, as compared to selective inhibition of C3 or CD14, the combined inhibition 
significantly more effectively attenuated IL-1β, TNF, IL-8 and MPO when preincubating the 
whole blood with the inhibitors. As compared to selective inhibition of C3, but not CD14, the 
combined inhibition significantly more effectively attenuated IL-6, MIP-1α and MIP-1β.  
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In conclusion, study II shows that the anti-inflammatory effect is gradually lessened and 
eventually lost as the time span between adding the bacteria and applying the inhibitors 
increase.  
 
Study III 
Thirty pigs were randomly allocated to a negative control group, a positive control group, or 
one of two intervention groups receiving either OmCI or OmCI and anti-CD14. In septic pigs, 
C5-inhibition completely abrogated complement activation and significantly attenuated the 
level of LTB4. C5-inhibition alone significantly attenuated expression of TF on granulocytes, 
formation of thrombin-antithrombin complexes (P<0.001), and formation of TNF and IL-6 
(P<0.05); the combined inhibition of C5 and CD14 completely abrogated or strongly 
inhibited the same biomarkers (P<0.001 for all). The combined inhibition also attenuated the 
formation of PAI-1 (P<0.05), IL-1β and IL-8, increased the formation of IL-10, and 
completely abrogated the expression of wCD11R3 and the fall in neutrophil cell count 
(P<0.001 for all). With regards to haemodynamics, combined inhibition of C5 and anti-CD14 
delayed the increase in heart rate by 60 min (P<0.05) and mean pulmonary artery pressure by 
30 min (P<0.01).  
 
In conclusion, study III clearly demonstrates that the combined inhibition exerts impressive 
and broad systemic anti-inflammatory effects in Gram-negative induced sepsis. 
 
Study IV 
Tissues from the same pigs used in study III were examined from the combined treatment 
group, the positive control group and the negative control group after four hours of increasing 
bacterial infusions. IL-1β and IL-6 were significantly attenuated in liver, kidney, lung and 
spleen. IL-8 was significantly attenuated in kidney, lung, spleen and heart, whereas MCP-1 
was significantly attenuated in liver, kidney, spleen and heart. The combined inhibition 
significantly attenuated tissue factor mRNA upregulation in spleen and IP-10 mRNA 
upregulation in heart, liver, spleen and kidney. Finally, C5aR mRNA downregulation was 
prevented in heart and kidney. The anti-inflammatory effects in lung and heart correlated with 
the delay in hemodynamic changes observed in study III. 
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In conclusion, study IV adds important information about the anti-inflammatory effects on 
organ-level, supporting the findings from study III, and indicating preserved organ function 
by the combined inhibition. 
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5. DISCUSSION 
 
The four studies constituting this thesis explore and elucidate the efficacy of the combined 
inhibition of a key complement molecule and CD14 on bacterial induced inflammation and 
sepsis. The different papers demonstrate the efficacy from several perspectives. In paper I, the 
preservation of the anti-inflammatory effects is demonstrated over a broad range of Gram-
negative and Gram-positive bacterial concentrations. In paper II, the effect when adding 
inhibitors delayed is demonstrated, in addition to statistically proving the superior anti-
inflammatory effect of the combined treatment as compared with single inhibition of either 
complement or CD14. In paper III, the systemic effects of the combined inhibition in vivo are 
demonstrated exploring haemodynamics, inflammatory biomarkers and haemostasis in 
porcine sepsis. In paper IV, the local effects of the combined inhibition are demonstrated 
exploring inflammatory and haemostatic biomarkers in septic porcine organs. These findings 
are important contributions to “proof of concept” of such combined inhibition. 
 
5.1 Upstream versus downstream inhibition 
As mentioned in the introduction, severe sepsis is a state of whole-body inflammation 
triggered by an infection, a condition with high morbidity and mortality (103). The initial 
triggering of the inflammatory state involves numerous biological systems (80,89,90,126). 
Previously, sepsis related research has tried to single out one of several downstream 
inflammatory mediators appearing early in the reaction in order to dampen the inflammation. 
This has mainly been done on the basis that mediators such as TNF, IL-1β, IL-6 and IL-8 are 
correlated with morbidity and mortality in sepsis (101,127-130). Despite promising 
experimental and preclinical results, increased survival has proven extremely difficult, not to 
say impossible to achieve on this basis (104-106). The inability of this approach to cause an 
overall reduction of inflammatory mediators has later been confirmed (131,132). 
 
As downstream inhibition of single inflammatory mediators failed, targeting upstream bottle-
necks of these biological systems in order to block several downstream inflammatory 
mediators and their secondary effects emerged as a possibility. The principle of this approach 
is to inhibit upstream as close to the interaction between PRRs and their ligands as possible. 
Increasing research material over the last decade has proven the principle of this approach, in 
particular when targeting complement or CD14, with net attenuation of several downstream 
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inflammatory mediators, such as TNF, IL-6, IL-8 and IL-1β (109,110,114,133,134), but also 
with in vivo studies suggesting increased survival (135,136). The concept of upstream 
inhibition of inflammation is therefore well founded and has superior anti-inflammatory 
potential as compared with downstream inhibition. 
 
The other side of the coin is however that such upstream inhibition of innate immunity may 
have adverse effects. One of the functions of the complement system is opsonisation for 
phagocytosis and clearance of bacteria (25,38). However, the problem with impaired 
opsonisation is solved by inhibiting downstream of C3, as cleavage of this molecule is the key 
to this function. In the case of Neisserial infections, the complement system is also 
responsible for lysis of the bacteria (38). Therefore, complete inhibition must be done with 
great care in order to avoid increasing the risk for new infections, rather than decreasing the 
unfavourable hyperinflammatory state observed in sepsis.  
 
Experience with complement inhibition already exists with PNH-patients, and the risk for 
Neisserial infections is indeed increased (137). This increase is however shown to be 
manageable with vaccinations and under certain circumstances prophylactic use of antibiotics. 
Similarly, case reports of C5 inhibition with concurrent use of antibiotics and vaccinations in 
patients with catastrophic anti-phospholipid syndrome (CAPS) have proven clinical benefit 
without adverse infections (138). Importantly, the PNH-patients receive complement 
inhibition over an extended period of time, whereas in the case of proposed sepsis treatment, 
the complement inhibition would be applied short term, either prophylactically to patients at 
risk for developing sepsis, or to patients with early signs and symptoms of sepsis (81). Both 
patient populations should under all circumstances be treated with antibiotics concomitantly.    
 
5.2 Single versus combined inhibition – redundancy of host defence. 
Several studies inhibiting either a key complement molecule or TLRs in sepsis prove to have 
anti-inflammatory effects, but often with some residue productions of the downstream 
inflammatory mediators, such as the cytokines mentioned above (109,115,133,134). Taking 
the numerous biological inflammatory systems activated in the course of sepsis, redundancy 
of host defence inflammatory mechanisms is a plausible explanation for this, and the using the 
potential to increase the anti-inflammatory effect by combining inhibition of two of the major 
inflammatory systems is one possible approach to overcome this problem, as set forward in 
the hypothesis proposed by professor Mollnes and colleagues (81).  
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In paper I and II, redundancy of host defence inflammatory mechanisms were demonstrated 
several times. MPO was the most obvious example, where single inhibition of complement or 
CD14 barely affected the level of MPO, whereas the combined inhibition had a striking effect, 
thereby demonstrating not only additive but also synergistic anti-inflammatory effects of the 
combined inhibition. Although not all readouts displayed such synergistic anti-inflammatory 
effects, all readouts in paper II, and most readouts in paper I and III point to an increased 
anti-inflammatory effect by the combined inhibition. Especially in paper I, the robustness of 
the combined inhibition was tested, and in comparison with selective inhibition of 
complement and CD14, the combined inhibition achieved a strikingly more sustainable anti-
inflammatory effect. In paper II, the anti-inflammatory effect of combined inhibition was 
tested against single inhibition and also proven to be statistically more effective. These 
observations are in line with previous and later research, in Gram-negative, Gram-positive 
and polymicrobial induced inflammation (111,112,115,139,140). 
  
In all papers but paper I, E. coli is the sole inflammation inducer, and the model is therefore 
relatively LPS-driven and CD14 dependent (56). In paper I, S. aureus is also used for 
inducing inflammation, and this model is relatively more complement driven (63,111). 
Although only hypothetically, one might assume that complement inhibition in S. aureus 
sepsis and CD14 inhibition in E. coli sepsis were sufficient to achieve proper anti-
inflammatory effect. However, acquiring a microbiological diagnosis is always time 
demanding and quite often ends up being inconclusive. The combined use of complement and 
CD14 inhibition would therefore still be of relevance (6,7). In further support of the combined 
inhibition in sepsis the microbiological diagnosis is often polymicrobial and thus both 
complement and CD14 should be inhibited. This being said, all data in this thesis indicate a 
clear anti-inflammatory benefit from the combined inhibition as compared with single 
inhibition, regardless of the causative bacteria being Gram-positive or Gram-negative.  
 
5.3 Ex vivo studies  
In the in vitro part of this thesis, one of the goals was trying to find new approaches to test the 
combined inhibition of complement and CD14 in an ex vivo sepsis model, simulating aspects 
of the clinical setting. Without any argument, ex vivo sepsis studies cannot ever become actual 
sepsis studies, but rather studies of bacterial induced inflammation. Although the whole blood 
model allows for all the components of the blood but thrombin to interact, the disadvantage is 
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that all other cell systems of the organism, including the sepsis relevant endothelium of the 
vascular system, are not part-takers in the induction of inflammation in this model. In addition, 
the blood is continuously exposed to air and plastic from the surface of the tubes, the latter 
being known to activate the complement system (112).      
 
Nevertheless, paper I and II were attempts to mimic some of the features of live sepsis and 
application of possible treatment regimen. In paper I, the gradually increased bacterial load 
was meant to resemble the different stages of sepsis, and previous research, especially in 
meningococcal disease, show a clear correlation of bacterial load in the patients and the 
disease severity (141). From a clinical point of view, although being far from the bedside, we 
therefore found it interesting to test to what extent the effect of the inhibitors would be 
preserved. The obvious con is of course that the efficacy was tested whilst under otherwise 
non-clinical circumstances, the inhibitors were for instance added prior to the bacteria. 
     
In the clinical setting, early onset treatment is of vital importance. To draw a comparison 
between antimicrobial treatment and mediator directed anti-inflammatory therapy, the sooner 
one may start treatment, the better and faster the response to the treatment. The likelihood of 
commencing antimicrobial treatment and anti-inflammatory treatment before the onset of the 
infection is small. Most of the research on complement and CD14 inhibition in sepsis has 
been conducted without delay between the onset of inflammation and the adding of 
complement- or CD14-inhibitors. What are really being tested under such circumstances are 
“proof of concept” and the efficacy of the inhibitors when used prophylactically. The main 
point of paper II was to test the ability of the combined inhibition to attenuate inflammation, 
also when adding the inhibitors after triggering the inflammatory mechanisms. The results 
which show that the effect was gradually lost with increasingly delayed addition of inhibitors, 
were not unexpected and underscore that in a possible future mediator directed therapy, 
aiming for “the sooner the better” would still be the only suitable approach.  
 
5.4 In vivo studies and the pig as model animal  
In vivo animal models are substitutes for real patients; however such models approximate live 
sepsis as closely as possible in preclinical research. Mice have been, and still are, the most 
used model animal for studying sepsis, and mice as model animal for sepsis research are still 
of great relevance. However, mice are not men and there are obvious disadvantages with the 
use of mice in sepsis research (142). In most aspects pigs are relatively more suitable animals 
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to study human sepsis as they have the advantage of displaying closer physiological, 
anatomical, genomic and immunologic resemblance to human (143,144). For these and 
practical reasons, the pig was chosen as the animal model in our studies. The pigs used in our 
experiments were only a few weeks of age and the size of the pigs was approximately 15 kg. 
It is therefore probably more correct to draw lines between this model and paediatric sepsis as 
both size and immunologic maturity will influence the inflammatory response (145).  
In a porcine sepsis model for human disease, awareness of pig peculiarities is also important; 
in particular the resident pulmonary intravascular macrophages are challenging (146). They 
resemble human liver Kupffer cells, engulf circulating microparticles including LPS of E. coli 
and constitutively express TLR4, which produce large amounts of proinflammatory cytokines 
such as IL-1β upon stimulation with LPS (146,147). The immunoreactive features of the 
porcine lung may explain the extremely rapid increase in MPAP caused by the intravenous 
infusions of the bacteria, a problem not commonly encountered in septic human patients.  
Investigating inflammatory mediators and the attenuation of such mediators by intervention is 
a common and relevant approach in sepsis research. One of the great advantages of in vivo 
studies is the ability to investigate relevant physiological parameters. Normalisation or at least 
improvement of cardiac and pulmonary function upon intervention in sepsis gives greater 
prospects of actual clinically significant effects as compared to net reduction of a single 
cytokine. In study III, the significant delay in haemodynamic changes is therefore of great 
interest. Furthermore, the link between reduced haemodynamic changes in study III and 
reduced pulmonary and cardiac inflammation observed in study IV strengthen the hypothesis 
that the combined inhibition may improve the function of vital organs in sepsis, whereby 
reducing the risk for multiple organ failure. As the number of failing organs is correlated to 
mortality in sepsis, it is of course tempting to speculate that the anti-inflammatory effect may 
also reduce mortality (6).   
On the other hand, one might argue that the duration of the delay in haemodynamic changes 
in study III was not particularly prolonged. However, the intravenous E. coli sepsis model 
used in our study was extremely forceful, and the piglets received bacterial loads leaving them 
on the brink of haemodynamic collapse within a very short period of time. The above 
described problems with increased MPAP also forced us to use relatively large amounts of 
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norepinephrine, and one might speculate that the delay in haemodynamic changes would have 
been more prolonged were it not for the use of norepinephrine. 
 
The model used in the study partly resembles the clinical picture of meningococcal disease 
with N. meningitides. However, there is no such thing as a standardized course of sepsis (148), 
and the vast majority of septic patients do not display such a rapid development of the disease 
(149). A less forceful model, such as the polymicrobial cecal ligation and puncture (CLP) 
model, would therefore likely be able to show a more prolonged delay in haemodynamic 
changes, and one might argue that a less forceful model would be preferable and maybe better 
suited also to possibly demonstrate increased survival (149). In support of this view, a mouse 
CLP study demonstrated increased survival by combined inhibition of CD14 and complement 
(139), and interestingly survival was also shown to be significantly increased as compared 
with the selective inhibition of complement and CD14. 
 
5.5 The relevance of readouts 
In sepsis, a “cytokine storm” is released as a response to the initial interaction between 
PAMPs and PRRs (150). All readouts in the papers were carefully selected with respect to 
their relevance in sepsis. TNF and IL-1β are known to be part of the early inflammatory 
response, whereas several other cytokines such as IL-6 and IL-8 are induced slightly later 
(18,151). These cytokines are key inflammatory mediators and have been considered possible 
therapeutic targets for intervention in sepsis. They have been shown to increase with 
morbidity and mortality in sepsis, and a decrease has been shown to correlate with the 
resolution of sepsis (98,100,105). Therefore, the broad net reduction of these inflammatory 
biomarkers in all papers constituting this thesis is of great relevance trying to explore the anti-
inflammatory potential of the combined inhibition.  
 
The soluble terminal complement complex (TCC) is another biomarker examined in all 
papers. When using a complement inhibitor as part of the intervention, the relevance of 
detecting soluble TCC is obvious as a massive reduction of TCC confirms that the 
complement inhibitor works in the model. Secondly, and especially interesting in the in vivo 
sepsis model, TCC has been shown to correlate with mortality in sepsis, at least in 
meningococcal disease (152), and changes in TCC therefore may also convey possible clinical 
relevance. TCC has readily been detected in vitro using ELISA, so also in paper I and II, but 
in porcine plasma samples, we have previously been unable to detect TCC. The explanation 
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for this is probably that the antibody used for detecting TCC in porcine plasma is based on 
cross-reactivity, but the sensitivity for porcine TCC is only moderate as compared to human 
TCC (120). In study III and IV we were able to access newly developed multiplex 
methodology whereby increasing the sensitivity for porcine TCC (123). Detection of TCC in 
plasma and organs was therefore an encouraging achievement in itself. The increase of TCC 
in plasma and tissues from the positive control group confirms the view that complement 
activation contributed to the inflammatory response in the in vivo model. In addition we may 
speculate that the significantly reduced levels of TCC in plasma and tissues from the animals 
receiving OmCI convey a possible clinical relevance of complement inhibition.   
 
The cross-talk between innate immunity and coagulation and fibrinolysis also makes relevant 
the examination of markers of coagulation and fibrinolysis (71,153,154). The convincing 
effect on TAT, PAI-1 and TF in study III, and TF and PAI-1 in spleen in study IV opens the 
possibility for reducing the risk for developing DIC by the combined inhibition; potentially of 
great significance given the clear relationship between development of DIC and mortality in 
sepsis (86-88).  
 
5.6 Future perspectives 
Paper III showed the effect of combined inhibition of complement and CD14 in vivo, and the 
effect was observed also in porcine organs in paper IV. These studies are preclinical “proof of 
concept” studies and importantly demonstrated that this kind of intervention is worth further 
studies. The prophylactic use of mediator directed inhibitors is so far not on the agenda in 
sepsis treatment. It may however be possible to find patients at risk for developing sepsis, and 
treat them prophylactically, but this remains a question for the future.  
 
Paper II explored ways to simulate the clinically relevant delay between the initial triggering 
of the inflammation and the intervention with complement and CD14 inhibition. More 
importantly the study opened the possibility for a therapeutic window of time, and as such this 
study constitutes a step towards more clinically relevant testing of the concept. Conducting an 
in vivo study, much like study III, but with delayed administration of the combined inhibition 
would be a next step in the hunt for possible clinical application of such treatment.  
Interestingly, a previous post-challenge study on the effect of an anti-C5a antibody in a mouse 
CLP-model demonstrated increased survival (155). Testing the concept of post-challenge 
combined inhibition of complement and CD14 in large animals using other sepsis models 
40 
 
such as the polymicrobial CLP-model, and also in models using other microbial agents such 
as S. aureus, would also be of great interest.  
 
As mentioned in the introduction, DAMPs and PAMPs appear largely to depend on the same 
PRRs to evoke inflammatory responses (9). Translational value of research on pathogen-
induced inflammation to sterile-induced inflammation may thus prove to be of significance. 
Research from our own group show that treatment with OmCI significantly reduced infarction 
size and improved cardiac contractility and function in a porcine model of cardiac ischemia-
reperfusion injury (personal communication with Søren E. Pischke). This finding is supported 
by existing research on the role of complement in ischemia-reperfusion injury (156,157). 
Even more interestingly, also TLR4 and TLR2 are shown to be implicated in this sterile 
inflammatory process (158,159), and expectations are attached to the testing of combined 
complement and CD14 inhibition in a similar ischemia-reperfusion model. As ischemia-
reperfusion injuries also occur in several other conditions such as cerebral infarction and 
transplantation, the possible clinical value of such research may prove to be substantial. 
  
41 
 
6. CONCLUSIONS 
 
This thesis clearly demonstrates that combined inhibition of complement and CD14 
effectively attenuates Gram-negative and Gram-positive bacterial induced inflammation, even 
when challenged with relatively high bacterial concentrations. Furthermore, the significance 
of delay between the initial triggering of inflammation and intervention is explored, and the 
results points to a possible therapeutic window of time. The anti-inflammatory effect of the 
combined inhibition of complement and CD14 on Gram-negative induced inflammation is 
also shown to be statistically superior to selective inhibition of complement as well as CD14.  
The anti-inflammatory effect of the combined treatment is demonstrated in vivo on a broad 
range of clinically relevant inflammatory, haemostatic and haemodynamic parameters. Lastly 
the anti-inflammatory effect of the combined inhibition is demonstrated also in organs. The 
correlation between the anti-inflammatory effects in organs and the delay in haemodynamic 
derangement observed, underscores possible future clinical relevance of the combined 
inhibition of complement and CD14.  
 
It is difficult to draw hard conclusions upon relatively small amounts of data. However, 
altogether the four studies prove the anti-inflammatory potential of the combined inhibition of 
complement and CD14, in Gram-negative and Gram-positive induced inflammation. The 
results of the in vivo studies in particular point to a potentially clinically relevant application 
of the combined inhibition of complement and CD14, although it is known that a lack of 
correlation between animal studies and clinical trials is not uncommon.  
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